Medullary Thyroid Carcinoma

Medullary thyroid carcinoma (MTC) is a rare type of cancer that develops in the thyroid, a butterfly-shaped gland located in the neck below the larynx (voice box). The thyroid is responsible for producing the hormones thyroxine (T4) and triiodothyronine (T3), which control important bodily functions such as heart rate, digestion, and body temperature.

Neuroendocrine cancers are a complex group of tumours that develop in the neuroendocrine system, which is responsible for regulating important bodily functions such as heart rate, blood pressure and metabolism. They most commonly develop in the gastro-intestinal tract, pancreas, and the lungs; however, they can develop anywhere in the body. These tumours develop from neuroendocrine cells, which are responsible for receiving signals from the nervous system and producing hormones and peptides (small proteins) in response.

MTCs generally develop from C cells (formerly known as parafollicular cells) in the thyroid, which are responsible for the production of the hormone calcitonin. Calcitonin is responsible for regulating the levels of calcium and potassium in the body.

The average age of diagnosis for MTC varies by subtype, and is generally diagnosed equally among the sexes. However, anyone can develop this disease.

Types of Medullary Thyroid Carcinoma

There are two primary types of MTC, which are classified by whether they occur sporadically or as a part of a genetic condition.

Sporadic Medullary Thyroid Carcinoma

Sporadic MTC is the most common subtype of this disease, and is not linked to any genetic mutations or syndromes. This subtype is generally diagnosed at an older age (between the ages of 40-60), and often presents as a singular nodule on the thyroid gland. Sporadic MTC is generally less aggressive than FMTC.

Familial Medullary Thyroid Carcinoma

Familial MTC (FMTC) is a less common subtype of disease, and is most commonly associated with the genetic condition multiple endocrine neoplasia syndrome type 2 (MEN2). It has also been associated with Von-Hippel Lindau (VHL) disease and neurofibromatosis type 1 (NF1). FMTC is caused by a mutation of the RET (rearranged during transfection) proto-oncogene. FMTC is generally diagnosed at a younger age (often under the age of 18), and often presents bilaterally on the thyroid gland. This type of tumour may be more aggressive than sporadic MTC.

Treatment

If a MTC is detected, it will be staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you.

Cancers can be staged using the TNM staging system:

  • T (tumour) indicates the size and depth of the tumour.
  • N (node) indicates whether the cancer has spread to nearby lymph nodes.
  • M (metastasis) indicates whether the cancer has spread to other parts of the body.

This system can also be used in combination with a numerical value, from stage 0-IV:

  • Stage 0: this stage describes cancer cells in the place of origin (or ‘in situ’) that have not spread to nearby tissue.
  • Stage I: cancer cells have begun to spread to nearby tissue. It is not deeply embedded into nearby tissue and had not spread to lymph nodes. This stage is also known as early-stage cancer.
  • Stage II: cancer cells have grown deeper into nearby tissue. Lymph nodes may or may not be affected. This is also known as localised cancer.
  • Stage III: the cancer has become larger and has grown deeper into nearby tissue. Lymph nodes are generally affected at this stage. This is also known as localised cancer.
  • Stage IV: the cancer has spread to other tissues and organs in the body. This is also known as advanced or metastatic cancer.

Cancers can also be graded based on the rate of growth and how likely they are to spread:

  • Grade I: cancer cells present as slightly abnormal and are usually slow growing. This is also known as a low-grade tumour.
  • Grade II: cancer cells present as abnormal and grow faster than grade-I tumours. This is also known as an intermediate-grade tumour.
  • Grade III: cancer cells present as very abnormal and grow quickly. This is also known as a high-grade tumour.

Once your tumour has been staged and graded, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. This is often performed after a biopsy, and can help guide treatment options for you.

Treatment is dependent on several factors, including location, stage of disease and overall health.

Treatment options for MTCs may include:

  • Surgery, potentially including:
    • Thyroidectomy.
    • Lymphadenectomy.
    • Neck dissection.
  • Watch and wait.
  • Radiation therapy, such as external beam radiation therapy.
  • Ablation therapy, potentially including:
    • Radiofrequency ablation (RFA).
    • Cryotherapy.
    • Embolisation.
  • Clinical trials.
  • Palliative care.

Risk factors

While the cause of sporadic MTC remain unknown, FMTC has been linked to mutations in the RET proto-oncogene, and may occur as a result of any of the following conditions:

  • Multiple endocrine neoplasia type 2 (MEN2).
  • Von-Hippel Lindau disease (VHL).
  • Neurofibromatosis type 1 (NF1).

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

Many people with a MTC may appear asymptomatic in the early stages of disease. As the tumour progresses, some of the following symptoms may appear:

  • Painless lump in the neck.
  • Difficulty swallowing.
  • Dyspnea.
  • Changes in the voice, such as hoarseness.
  • Lymphadenopathy in the neck.
  • Excess calcitonin, which carries its own set of symptoms:
    • Diarrhoea.
    • Facial flushing.
  • Excess adrenocorticotropic hormone (ACTH) (Cushing’s syndrome), which carries its own set of symptoms:
    • Unexplained weight gain (particularly in face, chest and abdominal areas).
    • Exaggerated facial roundness.
    • Thinning of arms and legs with muscle weakness.
    • Pink or purple stretch marks on the chest and/or abdomen.
    • Easy bruising.
    • New or increased hair growth.
    • Acne.
    • Hyperglycaemia.
    • Hypertension.
    • Weakening of bones, which may cause osteoporosis or easily broken bones.
    • Anxiety, irritability and/or depression.
    • Difficulties concentrating.
    • Delayed growth in children.

Patients with FMTC may have additional symptoms based on the genetic condition they have. For more information on your individual condition, please refer to the Rare Cancers Australia knowledgebase.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a MTC, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Imaging tests, potentially including:
    • Ultrasound.
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
  • Blood tests, such as to check calcitonin level.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.